RET Inhibitors in Advanced NSCLC, Tanya Guel-Pérez, MD
Targeted Therapy for Treatment-Naïve RET Fusion-Positive Lung CancersПодробнее
Emerging Agents and Combinations to Treat RET Fusion-Positive Lung CancersПодробнее
Clinical Trials of Immune Checkpoint Inhibitors as First Line Therapy for Advanced NSCLCПодробнее
RET Inhibition Research: Next StepsПодробнее
From Variant Functionality to Resistance in CancerПодробнее
Selpercatinib Induced Durable Efficacy in RET Fusion-Positive NSCLCПодробнее
Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients with advanced RET f...Подробнее
Targeted therapies (i.e.: multi-kinase inhibitors, RET, NTRK inhibitors) in advanced disease. 251Подробнее
Treatment of NSCLC With RET FusionsПодробнее
Targeting RET Alterations With Selective Inhibitor BLU-667Подробнее
RET inhibition in RET aberrant cancersПодробнее
Part 1 Investigator Insights: Emerging Multikinase Inhibitors in the Treatment of Thyroid CancersПодробнее
Next steps in NSCLC: checkpoint inhibitors plus cellular therapyПодробнее
Part 2 Investigator Insights: Emerging Multikinase Inhibitors in the Treatment of Thyroid CancersПодробнее
Targeted therapy for NTRK fusion-positive cancersПодробнее
When Should I Combine Checkpoint Inhibitors & Chemotherapy in Frontline Treatment of Advanced NSCLC?Подробнее
LIBRETTO-001: Targeting RET Fusions in Advanced-Stage NSCLCПодробнее
Selecting and Managing RET-Targeted Therapy in mNSCLCПодробнее